Kymera Therapeutics, Inc. (NASDAQ:KYMR) COO Jeremy G. Chadwick Sells 1,383 Shares

Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) COO Jeremy G. Chadwick sold 1,383 shares of the business's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $30.45, for a total transaction of $42,112.35. Following the transaction, the chief operating officer now owns 67,800 shares in the company, valued at approximately $2,064,510. This trade represents a 2.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Kymera Therapeutics Price Performance

NASDAQ KYMR traded up $0.35 during mid-day trading on Friday, hitting $32.89. The company's stock had a trading volume of 639,628 shares, compared to its average volume of 584,001. The firm has a market capitalization of $2.14 billion, a P/E ratio of -14.06 and a beta of 2.22. Kymera Therapeutics, Inc. has a 52-week low of $29.07 and a 52-week high of $53.27. The stock's fifty day simple moving average is $38.23 and its two-hundred day simple moving average is $43.40.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last posted its earnings results on Thursday, February 27th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.76) by ($0.12). The company had revenue of $7.39 million during the quarter, compared to analyst estimates of $14.81 million. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. On average, equities analysts forecast that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Remove Ads

Institutional Investors Weigh In On Kymera Therapeutics

Hedge funds have recently bought and sold shares of the business. Blue Trust Inc. grew its position in shares of Kymera Therapeutics by 74.8% in the 4th quarter. Blue Trust Inc. now owns 631 shares of the company's stock worth $25,000 after acquiring an additional 270 shares in the last quarter. Summit Investment Advisors Inc. raised its position in shares of Kymera Therapeutics by 9.0% during the 4th quarter. Summit Investment Advisors Inc. now owns 4,912 shares of the company's stock valued at $198,000 after acquiring an additional 406 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in Kymera Therapeutics by 27.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,336 shares of the company's stock worth $114,000 after purchasing an additional 504 shares during the last quarter. Harbor Capital Advisors Inc. boosted its holdings in Kymera Therapeutics by 1.7% in the fourth quarter. Harbor Capital Advisors Inc. now owns 40,987 shares of the company's stock worth $1,649,000 after purchasing an additional 684 shares during the period. Finally, KBC Group NV increased its stake in Kymera Therapeutics by 53.8% during the fourth quarter. KBC Group NV now owns 2,151 shares of the company's stock valued at $87,000 after purchasing an additional 752 shares during the last quarter.

Analyst Upgrades and Downgrades

Several research firms have recently commented on KYMR. HC Wainwright raised their price target on Kymera Therapeutics from $54.00 to $60.00 and gave the company a "buy" rating in a report on Friday, February 28th. BMO Capital Markets assumed coverage on Kymera Therapeutics in a report on Friday, December 6th. They issued a "market perform" rating and a $55.00 target price for the company. Wells Fargo & Company raised shares of Kymera Therapeutics from an "equal weight" rating to an "overweight" rating and upped their price target for the stock from $38.00 to $57.00 in a research note on Monday, December 2nd. Stephens reiterated an "overweight" rating and issued a $60.00 price target on shares of Kymera Therapeutics in a report on Tuesday, January 21st. Finally, Leerink Partners reissued an "outperform" rating and set a $60.00 price objective on shares of Kymera Therapeutics in a report on Friday, December 27th. Three research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $56.69.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.